Head and Neck Cancer Trial Results Showed Promising Gains
A combination therapy improved response rates for patients with advanced head and neck cancer in a phase 2 study.
Updated on Oct. 4, 2026 in Cancer
Live Poll
Should the FDA accelerate approval for new cancer treatments based on early-stage clinical trial data?
Inhibrx reported updated phase 2 trial data on September 8, 2026, showing that combining INBRX-106 with pembrolizumab improved outcomes for patients with head and neck squamous cell carcinoma. The results suggest the combination may be more effective than pembrolizumab alone for certain patients with high PD-L1 expression.
Why it matters
Expanding treatment options for advanced head and neck cancer is critical, as current therapies have limited effectiveness for many patients. This study aims to provide the necessary evidence to support an accelerated approval pathway for this combination therapy.
In a randomized phase 2 trial of 63 evaluable patients with high PD-L1 expression, the combination of INBRX-106 and pembrolizumab showed a 48.3% objective response rate compared to 26.5% for monotherapy. The combination also yielded a 72.4% six-month progression-free survival rate versus 42.8% for the control group.
The players
Inhibrx
A biotechnology company focused on developing protein therapeutics, including novel drug candidates for various cancers.
Pembrolizumab
A well-known immunotherapy drug that targets the PD-1 protein to assist the immune system in identifying and destroying cancer cells.
The details
The treatment works by pairing intravenous INBRX-106 with 200 mg of pembrolizumab, an immunotherapy agent that blocks the PD-1 pathway to help the immune system recognize and attack cancer cells. The trial enrolled patients with combined positive scores of 20 or greater to test whether this combination enhances the immune response in squamous cell carcinoma. Common side effects reported by participants included fatigue, diarrhea, and rash.
Timeline
May 2026: Earlier interim study data were reported.
August 19, 2026: The data cutoff date for the updated efficacy analysis occurred.
September 8, 2026: Inhibrx issued a news release regarding the study results.
May 2029: The estimated completion date for the trial is reached.
Health Landscape
This development follows the established pattern of using surrogate endpoints to expedite market entry through the FDA accelerated approval pathway. It adds to the growing field of combination immunotherapies aiming to improve upon standard single-agent PD-1 inhibitors in solid tumors.
While these trial results show promise, they are preliminary and do not change current standard-of-care guidelines for head and neck cancer. Patients interested in how these therapies might relate to their specific diagnosis should discuss current clinical trial opportunities with their oncologist.
The takeaway
This trial highlights the potential for combination immunotherapy to improve response rates for specific head and neck cancer patients. If you or a loved one are managing this condition, discuss the role of immunotherapy and current research trials with your physician.
Further reading
For more information on current treatment trends, visit our section on Cancer.
More information
Review the full study design and eligibility criteria on the official clinical trial registration page.
Source note: This article includes information reported by OncLive.
Live Poll
Should the FDA accelerate approval for new cancer treatments based on early-stage clinical trial data?
